HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bevan, J. A. Articles by Barnett, B. L. Search for Related Content PubMed PubMed Citation Articles by Bevan, J. A. Articles by Barnett, B. L.

Tc-99m HMDP (Hydroxymethylene Diphosphonate): A Radiopharmaceutical for Skeletal and Acute Myocardial Infarct Imaging. I. Synthesis and Distribution in Animals

Miami Valley Laboratories, The Procter & Gamble Company, Cincinnati, Ohio

Correspondence: For reprints contact: Andrew J. Tofe, PhD, Miami Valley Laboratories, P. O. Box 39175, Cincinnati, OH 45247.

ABSTRACT

Technetium-99m hydroxymethylene diphosphonate (Tc-99m HMDP) is a new diphosphonate skeletal imaging agent. Animal studies show that Tc-99m HMDP has a higher uptake on bone and a more rapid clearance from the blood than any of the three technetium-labeled bone imaging agents in current use: Tc-99m methylene diphosphonate (MDP), Tc-99m (1-hydroxyethylidene) diphosphonate (HEDP), and Tc-99m pyrophosphate (PPi). On the basis of these animal studies, Tc-99m HMDP is a highly promising candidate for skeletal imaging.